▁A 10.375
▁British 8.1875
▁ph 10.984375
arma 2.263671875
ce 1.90625
ut 1.669921875
ical 0.0694580078125
▁company 2.69921875
▁has 3.232421875
▁reported 5.7421875
▁positive 3.794921875
▁results 2.49609375
▁from 3.224609375
▁its 2.5625
▁clin 2.4453125
ical 0.1297607421875
▁trial 2.26953125
▁of 2.029296875
▁a 1.41796875
▁cancer 7.19140625
▁drug 1.8671875
. 1.251953125
▁However 5.1328125
, 0.1597900390625
▁anal 7.875
yst 0.383056640625
s 0.06781005859375
▁have 2.455078125
▁expressed 2.900390625
▁ca 3.18359375
ution 0.031494140625
, 3.1640625
▁warning 3.96875
▁that 0.5009765625
▁there 3.33203125
▁is 0.95947265625
▁still 1.5810546875
▁a 0.7314453125
▁long 1.3056640625
▁way 0.16064453125
▁to 0.12152099609375
▁go 0.0261688232421875
▁before 1.0361328125
▁the 1.3583984375
▁drug 2.853515625
▁can 1.427734375
▁be 0.43017578125
▁approved 1.5478515625
▁for 0.95263671875
▁use 1.3662109375
. 1.02734375
<0x0A> 0.88330078125
The 1.607421875
▁drug 1.7412109375
, 1.47265625
▁developed 4.3984375
▁by 0.06591796875
▁British 3.919921875
▁Bi 7.58203125
ote 0.7001953125
ch 0.4912109375
, 3.90625
▁is 1.6376953125
▁designed 2.81640625
▁to 0.044952392578125
▁target 2.845703125
▁a 1.6142578125
▁specific 1.4462890625
▁protein 1.072265625
▁that 1.58984375
▁is 0.68505859375
▁found 2.33203125
▁in 0.32177734375
▁many 2.990234375
▁types 1.4189453125
▁of 0.00472259521484375
▁cancer 0.300537109375
▁cells 1.369140625
. 0.505859375
▁In 4.05078125
▁the 1.6318359375
▁clin 1.3330078125
ical 0.010162353515625
▁trial 0.1195068359375
, 0.11907958984375
▁the 0.80615234375
▁drug 0.29931640625
▁was 0.20703125
▁tested 1.849609375
▁on 0.60498046875
▁patients 1.5517578125
▁with 0.286376953125
▁advanced 1.80859375
- 3.62109375
stage 0.017364501953125
▁can 2.541015625
cers 0.0005850791931152344
, 1.3828125
▁including 0.9111328125
▁pan 2.44921875
cre 0.0006866455078125
atic 0.0208740234375
▁cancer 1.0849609375
, 0.5546875
▁breast 1.6435546875
▁cancer 0.033538818359375
, 0.297607421875
▁and 0.73095703125
▁le 2.814453125
uk 0.25146484375
emia 0.00836944580078125
. 0.06915283203125
<0x0A> 0.8359375
Acc 3.423828125
ording 0.000568389892578125
▁to 0.0015115737915039062
▁the 0.5009765625
▁company 1.0888671875
, 0.31689453125
▁the 0.1505126953125
▁drug 0.357666015625
▁showed 2.81640625
▁prom 1.2119140625
ising 3.0159950256347656e-05
▁results 0.1199951171875
, 1.7001953125
▁with 0.55419921875
▁some 2.107421875
▁patients 0.1021728515625
▁experien 0.994140625
cing 1.71661376953125e-05
▁a 0.48095703125
▁reduction 1.5966796875
▁in 0.03387451171875
▁the 2.025390625
▁size 0.409423828125
▁of 0.05889892578125
▁their 0.55615234375
▁tum 0.038482666015625
ors 0.165283203125
▁and 1.59765625
▁surv 7.99609375
iving 1.927734375
▁longer 0.794921875
▁than 0.451171875
▁expected 1.2431640625
. 0.113037109375
▁However 0.55859375
, 0.00034499168395996094
▁the 0.6875
▁trial 2.650390625
▁was 0.306396484375
▁relatively 4.49609375
▁small 0.02728271484375
, 0.583984375
▁with 0.79248046875
▁only 0.344482421875
▁ 0.48193359375
3 1.91796875
0 1.166015625
▁patients 0.1292724609375
▁taking 2.484375
▁part 0.0435791015625
, 1.27734375
▁and 0.6513671875
▁the 1.126953125
▁drug 2.029296875
▁has 1.5302734375
▁yet 1.7900390625
▁to 0.00017762184143066406
▁be 0.33837890625
▁tested 2.5
▁in 0.55908203125
▁a 1.2109375
▁larger 0.3037109375
- 2.875
scale 0.004138946533203125
▁trial 1.9345703125
. 0.1488037109375
<0x0A> 0.1993408203125
Anal 3.5
yst 0.004474639892578125
s 0.00920867919921875
▁have 0.521484375
▁war 2.87890625
ned 0.0005154609680175781
▁against 4.07421875
▁getting 3.400390625
▁too 0.10833740234375
▁excited 0.240478515625
▁about 0.1781005859375
▁the 0.06787109375
▁results 1.251953125
, 1.3388671875
▁saying 2.36328125
▁that 0.1336669921875
▁it 2.662109375
▁is 0.4951171875
▁still 1.2802734375
▁too 0.402587890625
▁early 0.07757568359375
▁in 6.2265625
▁the 0.0362548828125
▁drug 1.43359375
▁development 4.109375
▁process 0.0230865478515625
▁to 0.25439453125
▁draw 1.2578125
▁any 0.85302734375
▁firm 2.0234375
▁conclus 0.004039764404296875
ions 2.396106719970703e-05
. 0.358642578125
▁They 1.0361328125
▁c 5.51171875
ite 0.94677734375
▁the 0.734375
▁fact 0.387939453125
▁that 0.0013780593872070312
▁many 4.03515625
▁prom 6.875
ising 2.1576881408691406e-05
▁cancer 1.115234375
▁dru 0.260986328125
gs 1.5497207641601562e-06
▁have 0.2454833984375
▁failed 0.62451171875
▁in 0.638671875
▁later 1.400390625
- 1.423828125
stage 0.01320648193359375
▁tri 1.0224609375
als 5.245208740234375e-06
, 0.2479248046875
▁either 7.55859375
▁because 0.486328125
▁they 0.495361328125
▁did 1.265625
▁not 0.00032973289489746094
▁work 1.271484375
▁as 0.86669921875
▁well 0.58740234375
▁as 0.09100341796875
▁expected 0.410888671875
▁or 0.254150390625
▁because 0.0875244140625
▁they 0.422607421875
▁had 2.29296875
▁un 1.9287109375
antic 3.396484375
ip 0.00011157989501953125
ated 0.00010597705841064453
▁side 0.026123046875
▁effects 0.02239990234375
. 0.058502197265625
<0x0A> 0.0928955078125
In 2.560546875
▁addition 1.63671875
, 0.10650634765625
▁the 0.75
▁analysis 4.7265625
▁of 1.5048828125
▁the 0.2442626953125
▁trial 1.3037109375
▁data 1.2197265625
▁has 1.0263671875
▁not 0.82177734375
▁yet 0.576171875
▁been 0.027740478515625
▁peer 2.666015625
- 0.1514892578125
review 0.0023174285888671875
ed 0.00011479854583740234
▁or 1.87890625
▁published 0.11279296875
▁in 0.2266845703125
▁a 0.05352783203125
▁medical 1.779296875
▁journal 0.0028934478759765625
, 0.43408203125
▁which 1.181640625
▁means 1.8642578125
▁that 0.165771484375
▁it 1.0947265625
▁has 3.041015625
▁not 0.0904541015625
▁been 0.271484375
▁subject 0.95849609375
▁to 1.359375
▁independent 2.9140625
▁scr 0.443359375
ut 0.00022590160369873047
iny 0.0002384185791015625
▁from 2.818359375
▁other 0.7666015625
▁exper 0.69189453125
ts 4.649162292480469e-06
▁in 1.0576171875
▁the 0.01148223876953125
▁field 0.015655517578125
. 0.0189056396484375
<0x0A> 0.89013671875
Des 2.12890625
p 0.00321197509765625
ite 7.987022399902344e-05
▁these 0.6787109375
▁cave 3.818359375
ats 0.0002123117446899414
, 0.00530242919921875
▁the 0.66015625
▁news 3.173828125
▁of 0.73681640625
▁the 0.2254638671875
▁positive 2.35546875
▁trial 1.396484375
▁results 0.034027099609375
▁has 0.474365234375
▁led 4.41015625
▁to 0.2034912109375
▁a 0.57958984375
▁sur 0.87451171875
ge 0.0002181529998779297
▁in 0.21337890625
▁British 9.640625
▁Bi 0.599609375
ote 0.0166473388671875
ch 0.01568603515625
' 0.9326171875
s 0.0009946823120117188
▁share 0.6279296875
▁price 0.0325927734375
, 0.51611328125
▁as 3.251953125
▁invest 0.1915283203125
ors 0.00272369384765625
▁hope 2.5859375
▁that 0.272216796875
▁the 0.057830810546875
▁drug 0.25537109375
▁will 0.77490234375
▁prove 3.4609375
▁to 0.137939453125
▁be 0.00814056396484375
▁a 0.265625
▁break 2.099609375
through 0.0014619827270507812
▁in 0.794921875
▁the 0.316650390625
▁fight 0.93896484375
▁against 0.0010461807250976562
▁cancer 0.01309967041015625
. 0.00817108154296875
<0x0A> 0.32421875
The 1.8212890625
▁company 2.193359375
▁has 0.72021484375
▁said 2.509765625
▁that 0.06964111328125
▁it 0.1455078125
▁plans 1.515625
▁to 0.0031604766845703125
▁continue 1.2958984375
▁testing 2.13671875
▁the 0.047088623046875
▁drug 0.00920867919921875
▁in 0.357177734375
▁further 2.849609375
▁tri 1.1171875
als 1.430511474609375e-06
, 0.453369140625
▁including 3.232421875
▁a 0.89013671875
▁larger 0.295166015625
- 0.269287109375
scale 0.002956390380859375
▁phase 4.359375
▁II 2.265625
▁trial 0.4091796875
▁that 2.064453125
▁will 0.46337890625
▁involve 1.9697265625
▁several 4.23828125
▁hundred 0.08917236328125
▁patients 0.2249755859375
. 0.301513671875
<0x0A> 1.185546875
If 2.62109375
▁the 0.3935546875
▁drug 0.5263671875
▁continues 5.74609375
▁to 0.01141357421875
▁show 0.1331787109375
▁prom 0.91064453125
ising 7.748603820800781e-06
▁results 0.007640838623046875
, 1.021484375
▁it 0.365234375
▁could 0.1512451171875
▁offer 5.0234375
▁a 0.70166015625
▁new 0.580078125
▁treatment 1.0966796875
▁option 0.148193359375
▁for 0.05316162109375
▁patients 0.330078125
▁with 0.1485595703125
▁advanced 0.2744140625
- 0.0999755859375
stage 0.0037555694580078125
▁can 0.2066650390625
cers 3.063678741455078e-05
▁who 3.9453125
▁currently 4.9453125
▁have 0.042694091796875
▁limited 2.904296875
▁options 0.315185546875
. 0.1834716796875
▁However 1.8330078125
, 0.00014007091522216797
▁it 0.9091796875
' 5.05078125
s 0.0012006759643554688
▁important 0.328369140625
▁to 0.020477294921875
▁note 1.130859375
▁that 0.0004246234893798828
▁it 3.140625
▁will 3.423828125
▁be 1.72265625
▁several 1.60546875
▁more 3.818359375
▁years 0.044036865234375
▁before 0.042144775390625
▁the 0.294189453125
▁drug 0.03582763671875
▁is 0.3310546875
▁likely 3.119140625
▁to 0.0032024383544921875
▁be 0.2423095703125
▁approved 0.875
▁for 0.1060791015625
▁use 0.426513671875
, 1.591796875
▁assuming 7.16015625
▁that 1.0322265625
▁it 0.88232421875
▁continues 2.294921875
▁to 0.0277862548828125
▁show 0.243408203125
▁positive 0.475341796875
▁results 0.0301971435546875
▁in 0.11956787109375
▁later 2.294921875
- 0.57666015625
stage 0.01422119140625
▁tri 0.1553955078125
als 2.1457672119140625e-06
. 0.0172576904296875
<0x0A> 0.08270263671875
In 1.837890625
▁the 0.44580078125
▁meant 0.06146240234375
ime 4.887580871582031e-06
, 0.00028204917907714844
▁patients 1.5556640625
▁with 0.6591796875
▁cancer 2.375
▁will 2.009765625
▁continue 1.2705078125
▁to 0.0087127685546875
▁rely 0.31494140625
▁on 0.01043701171875
▁existing 1.0458984375
▁treat 0.64013671875
ments 5.7220458984375e-06
, 0.6220703125
▁such 0.7978515625
▁as 0.0002334117889404297
▁chem 0.319580078125
other 0.01531982421875
apy 0.00542449951171875
▁and 0.55078125
▁radiation 0.195068359375
▁ther 0.35302734375
apy 0.0036563873291015625
, 0.137451171875
▁which 0.71435546875
▁can 1.5341796875
▁be 0.50341796875
▁effective 2.08203125
▁but 0.53662109375
▁also 2.734375
▁have 1.20703125
▁significant 2.05078125
▁side 0.027923583984375
▁effects 0.0026702880859375
. 0.369873046875
<0x0A> 0.400390625
The 2.208984375
▁news 2.771484375
▁of 0.066162109375
▁the 0.34130859375
▁positive 0.1351318359375
▁trial 0.1290283203125
▁results 0.005687713623046875
▁also 5.140625
▁highlight 3.064453125
s 0.11712646484375
▁the 0.038116455078125
▁on 4.11328125
going 0.00872039794921875
▁efforts 2.861328125
▁to 1.66015625
▁develop 0.46142578125
▁new 0.3896484375
▁and 1.96875
▁better 1.4599609375
▁treat 0.45751953125
ments 1.0371208190917969e-05
▁for 0.01499176025390625
▁cancer 0.1033935546875
, 1.42578125
▁a 3.30859375
▁disease 1.0537109375
▁that 0.09893798828125
▁affect 1.841796875
s 6.473064422607422e-05
▁millions 1.7119140625
▁of 0.01387786865234375
▁people 0.01959228515625
▁around 1.2978515625
▁the 9.751319885253906e-05
▁world 0.0256195068359375
. 0.370361328125
▁While 3.67578125
▁progress 4.2734375
▁has 0.595703125
▁certainly 6.91015625
▁been 0.0065765380859375
▁made 0.0174407958984375
▁in 0.63134765625
▁recent 0.325927734375
▁years 0.0379638671875
, 0.03924560546875
▁as 7.51953125
▁seen 4.0859375
▁in 0.60595703125
▁the 0.090087890625
▁development 1.86328125
▁of 0.0130615234375
▁new 1.044921875
▁imm 3.177734375
un 0.033447265625
other 0.0003898143768310547
apy 0.7138671875
▁dru 0.427490234375
gs 9.5367431640625e-07
▁and 1.2177734375
▁other 1.474609375
▁target 2.998046875
ed 0.0005702972412109375
▁ther 0.88330078125
ap 0.00334930419921875
ies 2.86102294921875e-06
, 0.06903076171875
▁there 0.352294921875
▁is 0.1361083984375
▁still 0.039306640625
▁much 1.7353515625
▁work 0.7353515625
▁to 0.035186767578125
▁be 0.05303955078125
▁done 0.0002732276916503906
▁to 1.76953125
▁improve 1.599609375
▁out 2.001953125
comes 0.0044708251953125
▁for 0.04412841796875
▁cancer 0.95068359375
▁patients 0.0006403923034667969
. 0.107177734375
<0x0A> 0.07391357421875
As 3.943359375
▁the 1.0791015625
▁development 3.99609375
▁of 0.08221435546875
▁new 0.177978515625
▁cancer 1.705078125
▁dru 1.1025390625
gs 2.7418136596679688e-06
▁continues 0.361328125
, 0.1732177734375
▁it 0.393310546875
' 1.5341796875
s 0.0012636184692382812
▁important 0.113037109375
▁for 2.4375
▁patients 0.131103515625
▁and 1.1787109375
▁their 0.2080078125
▁families 0.6845703125
▁to 0.0033931732177734375
▁stay 1.865234375
▁informed 0.30712890625
▁about 0.68701171875
▁the 0.2100830078125
▁latest 0.10516357421875
▁research 1.603515625
▁and 0.2000732421875
▁to 2.716796875
▁work 3.107421875
▁closely 2.55859375
▁with 0.0004763603210449219
▁their 0.048004150390625
▁health 1.986328125
care 0.1529541015625
▁prov 0.330078125
iders 6.937980651855469e-05
▁to 0.09564208984375
▁explore 6.1484375
▁all 0.4560546875
▁available 1.4599609375
▁treatment 0.347412109375
▁options 0.0011930465698242188
. 0.025634765625
<0x0A> 0.37109375
U 4.81640625
lt 0.92822265625
imately 0.0272674560546875
, 0.0018758773803710938
▁the 0.5869140625
▁hope 3.59765625
▁is 0.0643310546875
▁that 0.031097412109375
▁new 2.166015625
▁cancer 1.43359375
▁dru 0.2666015625
gs 5.960464477539062e-07
▁like 1.939453125
▁the 1.490234375
▁one 0.1397705078125
▁being 3.37109375
▁developed 1.8896484375
▁by 0.005603790283203125
▁British 0.07684326171875
▁Bi 0.021820068359375
ote 0.0007843971252441406
ch 0.00978851318359375
▁will 0.5263671875
▁prove 3.736328125
▁to 0.08892822265625
▁be 0.01788330078125
▁safe 5.78125
▁and 0.07952880859375
▁effective 0.01509857177734375
▁treat 2.484375
ments 7.62939453125e-06
▁that 0.42333984375
▁can 0.2037353515625
▁improve 1.7099609375
▁the 0.92138671875
▁lives 0.6708984375
▁of 0.004913330078125
▁millions 5.64453125
▁of 0.00957489013671875
▁people 0.88037109375
▁around 0.767578125
▁the 0.00014984607696533203
▁world 0.01406097412109375
. 0.07940673828125
▁But 5.4765625
▁until 1.4736328125
▁then 0.81591796875
, 0.00394439697265625
▁ca 7.1328125
ution 0.0019435882568359375
▁is 0.4375
▁war 2.927734375
r 0.0006256103515625
anted 0.0026035308837890625
, 1.3095703125
▁and 1.1943359375
▁continued 5.0625
▁research 0.87158203125
▁and 1.3466796875
▁development 0.55126953125
▁are 2.2578125
▁cru 2.705078125
cial 0.0008254051208496094
. 2.1640625
